ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37600482

Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.

Zhang Z and 3 others. EClinicalMedicine, 2023. Cited by 20 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials. Papers, record 37600482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37600482

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
PubMed
Journal
EClinicalMedicine
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.25
iCite
Revised in PubMed
2024-09-23
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang ZZhishan
2Pan QQunxiong
3Lu MMingdong
4Zhao BBin

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References190

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,863,955Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med2018https://conductscience.org/library/papers/29863955PubMed
233,439,693Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).J Clin Oncol2021https://conductscience.org/library/papers/33439693PubMed
329,023,213
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
J Clin Oncol2017https://conductscience.org/library/papers/29023213PubMed
430,262,187Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.Lancet Oncol2018https://conductscience.org/library/papers/30262187PubMed
533,657,295Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med2021https://conductscience.org/library/papers/33657295PubMed
635,279,527Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.ESMO Open2022https://conductscience.org/library/papers/35279527PubMed
733,485,464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
832,971,005
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol2020https://conductscience.org/library/papers/32971005PubMed
933,894,335Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.Ann Oncol2021https://conductscience.org/library/papers/33894335PubMed
1027,718,784Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.N Engl J Med2016https://conductscience.org/library/papers/27718784PubMed

1 to 10 of 190

See all 190 references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42,876,499A novel multimodal model integrating CT-based deep learning and clinical information for predicting 1-year OS of first-line immunotherapy in ES-SCLC patients.Front Oncol2026https://conductscience.org/library/papers/42876499PubMed
42,591,661FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy.Front Immunol2026https://conductscience.org/library/papers/42591661PubMed
42,567,977Artificial intelligence in drug discovery - what it is, where we stand and the path forward.Nat Rev Drug Discov2026https://conductscience.org/library/papers/42567977PubMed
42,117,884Risk-Benefit of Phase 2 Monotherapy Trials in Adult Solid Cancers: A Systematic Review and Meta-Analysis.Int J Cancer2026https://conductscience.org/library/papers/42117884PubMed
41,701,164Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.Oncologist2026https://conductscience.org/library/papers/41701164PubMed
41,293,268Comparative effectiveness and safety of immunotherapeutic strategies in ovarian cancer: a systematic review and network meta-analysis.Front Oncol2025https://conductscience.org/library/papers/41293268PubMed
40,887,652
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.
Exp Hematol Oncol2025https://conductscience.org/library/papers/40887652PubMed
40,519,225Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis.BMJ Oncol2025https://conductscience.org/library/papers/40519225PubMed
40,498,375Comparative Analysis of the TCR Repertoire in Bone Marrow CD8+ T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia.Eur J Immunol2025https://conductscience.org/library/papers/40498375PubMed
40,213,551A system review of neoadjuvant immune checkpoint blockade for breast cancer.Front Immunol2025https://conductscience.org/library/papers/40213551PubMed

1 to 10 of 16

See all 16 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37600482

GET https://conductscience.org/api/papers/v1/37600482/references?page=2

API referenceFor AI assistants